Purpose: Atezolizumab is an established treatment option for pretreated urothelial
carcinoma, demonstrating efficacy in phase II/III trials. The SAUL study enrolled a broader …

Background and objective We assessed the safety of atezolizumab in unselected patients
(including understudied populations typically excluded from clinical trials) with pretreated …

Background Atezolizumab, a humanised monoclonal antibody targeting PD-L1, is approved
for locally advanced/metastatic urothelial carcinoma. SAUL evaluated atezolizumab in a …

4519 Background: Atezo, a monoclonal antibody targeting PD-L1, is an approved therapy
for locally advanced/metastatic UC based on IMvigor210 and IMvigor211 phase II and III …

Background Conventional criteria for tumor progression may not fully reflect the clinical
benefit of immunotherapy or appropriately guide treatment decisions. The phase II …

AIMS OF THE STUDY Atezolizumab is an approved therapy for urothelial carcinoma based
on results from the IMvigor 210 and IMvigor211 phase II and III trials. The global SAUL study …

Background Atezolizumab (anti–programmed death-ligand 1) was approved in the USA,
Europe, and elsewhere for treatment-naive and platinum-treated locally …

Background IMvigor130 demonstrated statistically significant investigator-assessed
progression-free survival benefit with first-line atezolizumab plus platinum-based …

Background Patients with metastatic urothelial carcinoma have few treatment options after
failure of platinum-based chemotherapy. In this trial, we assessed treatment with …

Background Atezolizumab (ATZ) has demonstrated antitumor activity and manageable
safety in previous studies in patients with locally advanced or metastatic platinum-resistant …